Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 471

Sort by

Sort Order Select

Journal Articles

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Blood (2021) 137 (23): 3272–3276.

https://doi.org/10.1182/blood.2020008865

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

Fraser Soares, Branson Chen, Jong Bok Lee, Musaddeque Ahmed, Dalam Ly, Enoch Tin, Hyeonjeong Kang, Yong Zeng, Nayeema Akhtar, Mark D. Minden, Housheng Hansen He, Li Zhang

Blood (2021) 137 (16): 2171–2181.

https://doi.org/10.1182/blood.2019004108

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

Virus-specific T-cell therapies for patients with primary immune deficiency

Michael D. Keller, Catherine M. Bollard

Blood (2020) 135 (9): 620–628.

https://doi.org/10.1182/blood.2019000924

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong

Blood (2020) 135 (5): 387–391.

https://doi.org/10.1182/blood.2019003293

Published: 2020

Includes: Supplemental data

Journal Articles

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Lei Xiao, PhD

Blood (2019) 134 (Supplement_1): 4631.

https://doi.org/10.1182/blood-2019-130703

Published: 2019

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD

Blood (2019) 134 (Supplement_1): 929.

https://doi.org/10.1182/blood-2019-128468

Published: 2019

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, Phillip A Hsieh, Metin Kurtoglu, MD PhD, Yi Zhang, C Andrew Stewart, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1811.

https://doi.org/10.1182/blood-2019-121595

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy

Stefanie Herda, PhD, Andreas Heimann, MSc, Stefanie Althoff, MSc, Josefine Ruß, Lars Bullinger, Dieter Beule, PhD, Benedikt Obermayer, PhD, Il-Kang Na, MD

Blood (2019) 134 (Supplement_1): 1943.

https://doi.org/10.1182/blood-2019-124736

Published: 2019

Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 1942.

https://doi.org/10.1182/blood-2019-131892

Published: 2019

Journal Articles

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Blood (2019) 134 (Supplement_1): 2069.

https://doi.org/10.1182/blood-2019-127969

Published: 2019

NARROW

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Virus-specific T-cell therapies for patients with primary immune deficiency

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only